Public disclosures

Jiang Wenbin

Company insiders · PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
12
Buy lines
0
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-1112

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 762842 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.

2026-11-182026-11-20

57,212 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 270692 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.

2026-11-182026-11-20

29,002 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 117873 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.

2026-11-182026-11-20

22,100 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 15713 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.

2026-11-182026-11-20

11,781 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5633865 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

22,513 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5656378 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

57,212 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5599166 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

11,413 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5610579 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

29,002 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5581577 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

8,697 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5590274 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

22,100 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5568174 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

4,636 shares/units

SEC 4
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5572810 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

11,781 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement